Our analysis identified that 18% (n=7/49) of patient tumours in the NCT00524303 clinical trial, had an increase of AKT (S473) phosphorylation of >20% and a concurrent decrease in MAPK (T202/Y204) phosphorylation of >20% after 14 days of treatment with HER2-targeted therapies. This evidence concerns the gene ERBB2 and neoplasm.